@prefix dcterms: . @prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix Protein: . @prefix hgnc: . @prefix geneProductOf: . @prefix proteinModification: . @prefix psimod: . @prefix species: . @prefix occursIn: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 geneProductOf: hgnc:11935; a Protein: . sub:_2 belv:variantOf hgnc:6877; a proteinModification:, psimod:00696 . sub:_3 occursIn: species:9606; rdf:object sub:_2; rdf:predicate belv:increases; rdf:subject sub:_1; a rdf:Statement . sub:assertion rdfs:label "p(HGNC:CD40LG) -> p(HGNC:MAPK3,pmod(P))" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_5; pav:version "1.4" . sub:_4 prov:value "MCP-1 protein expression induced by IFN-gamma and CD40L (24 hours) was significantly decreased by the ERK1/2 MAPK pathway inhibitor, U0126. U0126 treatment at 10 micromol/L significantly reduced IFN- gamma and CD40L-induced MCP-1 protein production, bringing the levels of MCP-1 to baseline."; prov:wasQuotedFrom pubmed:11839576 . sub:_5 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:11839576; prov:wasDerivedFrom beldoc:, sub:_4 . } sub:pubinfo { this: dcterms:created "2014-07-03T14:30:00.961+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }